WuXi Biologics completed the acquisition of a Wuppertal facility from Bayer for £101m.

WuXi Biologics, a global open-access biologics technology platform, completed the acquisition of a Wuppertal facility from Bayer, a global enterprise with core competencies in the Life Science fields of health care and agriculture, for £101m. “This also marks an additional contribution by Bayer in the fight against the pandemic,” Timo Flessner, Bayer Site Manager.